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Abstract: Recent analysis of clinical trials on estrogen therapy proposes the existence of a therapeutic
window of opportunity for the cardiovascular benefits of estrogens, which depend on women’s age
and the onset of therapy initiation. In this study, we aimed to determine how vascular senescence and
the onset of estrogen treatment influence the common carotid artery (CCA) function in senescent and
non-senescent females. Ovariectomized female senescence-accelerated (SAMP8) or non-senescent
(SAMR1) mice were treated with vehicle (OVX) or 17β-estradiol starting at the day of ovariectomy
(early-onset, E2E) or 45 days after surgery (late-onset, E2L). In SAMR1, both treatments, E2E and E2L,
reduced constriction to phenylephrine (Phe) in CCA [(AUC) OVX: 193.8 ± 15.5; E2E: 128.1 ± 11.6;
E2L: 130.2 ± 15.8, p = 0.004] in association with positive regulation of NO/O2- ratio and increased
prostacyclin production. In contrast, E2E treatment did not modify vasoconstrictor responses to
Phe in OVX-SAMP8 and, yet, E2L increased Phe vasoconstriction [(AUC) OVX: 165.3 ± 10; E2E:
183.3 ± 11.1; E2L: 256.3 ± 30.4, p = 0.005]. Increased vasoconstriction in E2L-SAMP8 was associated
with augmented thromboxane A2 and reduced NO production. Analysis of wild-type receptor alpha
(ERα66) expression and its variants revealed an increased expression of ERα36 in E2L-SAMP8 in
correlation with unfavorable effects of estrogen in those animals. In conclusion, estrogen exerts
beneficial effects in non-senescent CCA, regardless of the initiation of the therapy. In senescent CCA,
however, estrogen loses its beneficial action even when administered shortly after ovariectomy and
may become detrimental when given late after ovariectomy. Aging and onset of estrogen treatment
are two critical factors in the mechanism of action of this hormone in CCA.
Keywords: estrogen; aging; estrogen receptor variants; cerebrovascular function; menopause;
hormone replacement therapy
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1. Introduction
The female aging process and associated disorders may be linked to changes in the hormonal
milieu [1]. Of all aging-related disorders, cardiovascular disease is the leading cause of morbidity
and mortality in older women [2]. Although estrogen modulates several pathways that are closely
associated with aging, it remains unknown whether estrogen can delay cardiovascular senescence, or
how estrogen-mediated responses occur in a senile vasculature.
In 1985, the observational study Nurses’ Health Study reported that estrogen therapy reduces
the risk of cardiovascular disease in postmenopausal women [3]. In agreement with these clinical
data, many experimental studies demonstrated that estrogen has beneficial effects in several signaling
pathways in the vascular system [4–9]. However, double-blind, randomized clinical trials—such as
Woman’s Health Initiative (WHI) and Heart and Estrogen/progestin Replacement Study (HERS I
and II)—showed that estrogen therapy increases cardiovascular risk, and more specifically the risk
for stroke in postmenopausal women [10,11]. Stroke is the leading cause of prolonged disability and
the third leading cause of death among women [2]. Despite this, there is still a concerning gap in the
comprehension of the mechanisms involved in the estrogen regulation of the cerebrovascular function
of aged women.
Among the explanations for the discrepancies between clinical trial and observational studies,
is the fact that women included in these trials were on average 60 years of age when they started
receiving estrogen therapy, typically more than 10 years after the onset of menopause. While in
the first observational study, women were younger, approximately 50 years of age, and closer to
menopause when they initiated hormonal therapy. Detailed analysis by aging groups suggests that
early initiation of estrogen therapy produces more favorable results than the average of late-onset
used in most trials [12]. These analyzes led scientists to conceive the so-called “timing hypothesis”,
which relies on the concept that estrogen has beneficial effects if taken before, or close to, the onset of
menopause when the detrimental aging effects or lack of estrogen in the vasculature have not yet been
established [13]. In 2016, the clinical trial ELITE (Early versus Late Intervention Trial with Estradiol)
strengthened this theory by showing that estrogen therapy is associated with less progression of
subclinical atherosclerosis only when it is initiated within six years after menopause onset [14]. Aging
per se is known to cause a series of alterations in the endogenous mechanisms that control vascular
function, leading to subsequent increased risk of cerebrovascular disease [15]. Moreover, vascular
aging can alter estrogen-mediated signaling pathways [16] and, as a consequence, estrogen therapy
may become harmful rather than beneficial to the vasculature.
The classical effects of estrogen in the vasculature are mediated via interactions with two subtypes
of nuclear receptors belonging to a superfamily of hormone-inducible transcription factors (ERα and
ERβ), and by a seven-transmembrane G protein-coupled ER, termed GPER, associated to activate
rapid signaling cascades after estrogen binding (for review, see [17]). Although the three estrogen
receptors are known to promote cardiovascular effects, ERα is the most associated with the beneficial
effects of estrogen in the endothelial and smooth muscle cells [17]. Furthermore, molecular studies
have identified and cloned alternative splicing variants of ERα, which have been associated with
modifications in the activation of the major signaling pathways by this receptor [17–19]. These splicing
variants of ERα dimerize with the wild-type 66Kd receptor (ERα66), and may serve as a competitive
inhibitor of ERα66 binding to DNA [18,19] and, therefore, an increase of ERα splicing may interfere
with ERα66 transcriptional activity function. Upregulation of this variant has been associated with
rapid estrogen and anti-estrogen signaling in gynecological cancer [20], although little is known about
their correlation with cardiovascular disease.
In this study, we interrogate the complicated relationship between the timing of estrogen therapy
and senescence in the protection or detriment of female cerebrovasculature. The common carotid
arteries (CCA) carry the main supply of blood to the brain, and inadequate circulation of blood through
these vessels may result in cerebrovascular events. We hypothesized that vascular senescence and the
onset of estrogen treatment modifies arterial function in association with changes in the expression
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of variants of classical ERα. For this purpose, we analyzed vascular reactivity of the CCA from
ovariectomized (OVX) senescence-accelerated prone (SAMP) mice following early- or late-onset of
estrogen treatment. Our previous studies have established OVX-SAMP as a model that closely mimics
menopause in women, as it can concomitantly determine vascular changes by estrogen withdrawal
(or replacement) in a senescent environment [21].
2. Material and Methods
2.1. Animal Models and Hormonal Treatment
Female senescence-prone inbred (SAMP8, aging model n = 80) and senescence-resistant inbred
strain (SAMR1, young control n = 80) mice, were obtained from the breeding stock at Parc Cientific
de Barcelona. The senescence-accelerated mouse model was developed as a result of selective
inbreeding of mice showing a phenotype of severe exhaustion (SAM-prone) and inbreeding of a
normal phenotype (SAM-resistant). SAMP strains are known to manifest spontaneously various
pathobiological phenotypes, including vascular senescence. SAM offers several advantages in aging
cardiovascular research as it ages fast and predictably, allowing the execution of experimental work in
a convenient and standard time course [21]. The animals were housed at the Animal Facility of the
University of Barcelona according to institutional guidelines (constant room temperature 22 ◦C, 12-h
light/dark cycles, 60% humidity, standard mice chow, and water ad libitum). All the procedures used
in this study were approved and performed following the guidelines of the Ethics Committee of the
University of Barcelona (Protocol 272/12), the Institute of Biomedical Sciences, University of São Paulo
(ICB-USP—Protocol 64, page 20, book 3. 27.05.2014), and in agreement with the Guide for the Care and
Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No.85-23,
revised 1996). At six months of age, SAMR1 and SAMP8 mice were ovariectomized under controlled
inhalant anesthesia with isoflurane (4% induction and 1.5–2% maintenance). After ovariectomy, mice
were divided into three groups: (1) ovariectomized treated with vehicle (OVX); (2) early onset of
estrogen treatment, initiated in the first day of ovariectomy (E2E); and (3) late onset of estrogen
treatment, initiated 45 days after ovariectomy (E2L). Cyclic estrogen therapy (5 µg/kg of 17β-estradiol
diluted in mineral oil), was administrated by subcutaneous injections every third day in order to
provide a more physiological hormonal milieu [16]. The efficacy of ovariectomy and estrogen treatment
was determined by the uterine weight and plasma estrogen concentrations. Sixty days following the
ovariectomy, all mice were euthanized with sodium pentobarbitone (85 mg/Kg, I.P.) and the CCAs
were dissected and kept in ice-cold physiological salt solution and prepared for different experiments
mainly as described [22].
2.2. Vascular Function Study
Segments (2 mm) of CCA with intact endothelium were mounted on an isometric wire myograph
(model 410 A; J.P. Trading, Aarhus, Denmark), as previously described [22]. The myograph was filled
with modified Krebs solution ((in mM): NaCl 130; NaHCO3 14.9, KCl 4.7, KH2PO4 1.18, MgSO4 1.17;
CaCl2.2H2O 1.56, EDTA 0,026 and glucose 5.5), and kept at 37 ◦C, 95% O2 and 5% CO2. After 60 min
(min) of equilibration, CCA segments were stimulated three times (10-min interval) with a KCl 60 mM
solution until the contraction reached a stable plateau (~15 min). After washout and return to a stable
baseline, consecutive concentration–response curves—with acetylcholine (ACh, 10−10 to 3 × 10−5 M),
phenylephrine (Phe, 10−9 to 10−5 M), and sodium nitroprusside (SNP, 10−10 to 3 × 10−5 M)—separate
by washout and 30 min intervals, were performed in the absence or the presence of several inhibitors.
In some experiments, contraction to the thromboxane A2 analog (U46619, 10−9 to 10−5 M), instead of
Phe was performed. Vasodilation to ACh and SNP were performed in U46619 (10−7 M) pre-contracted
vessels. The contribution of the different endothelium-derived factors to the vascular responses was
determined by treating isolated CCA segments with one of the following inhibitors: (1) nonselective
nitric oxide synthase (NOS) inhibitor Nω-nitro-L-arginine methyl ester (L-NAME; 10−4 M); (2) O2−
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scavenger (Tempol, 10−5 M); (3) non-selective COX inhibitor (Indomethacin, 10−6 M); (4) selective
COX-1 inhibitor (SC560, 10−5 M); or (5) selective COX-2 inhibitor (NS398, 10−6 M). Experiments were
done in parallel with segments from the same animal. Contractions to Phe and U46619 are shown as a
percentage (%) of the contractile response to 60mM KCl. Relaxations to ACh and SNP were expressed
as the percentage (%) of U46619 precontraction. The area under the concentration–response curve
(AUC) was used as an overall measure of cumulative responses induced by agonists in the presence of
vehicle or specific inhibitors.
2.3. Quantitative Real-Time PCR (qPCR) for Detection of COX and eNOS Expression
Total RNA was isolated from CCA using TRizol® reagent (Sigma-Aldrich, St Louis, MI, USA)
according to the manufacturer’s instructions. The amount of mRNAs encoding the COX isoforms
(COX-1 and COX-2) and downstream enzymes (PGI2S and TXA2S), as well as eNOS, were quantified
by qPCR based on SYBR® Green fluorescence (Applied Biosystems, Carlsbad, CA, USA). β-actin was
used as an internal control. Primer sequences are described in Table S3 (Major Resources Tables). qPCR
reactions were performed, recorded, and analyzed using the Corbett Research system (Corbett Life
Sciences, Sydney, Australia). The conditions for qPCR were as follows: 95 ◦C for 2 min, 40 cycles
of 95 ◦C for 15 s (s), and 60 ◦C for 1 min. Cycle threshold (Ct) values obtained for each gene were
referenced to β-actin (∆Ct) and converted to the linear form using the term 2−∆∆Ct as a value directly
proportional to the copy number of complementary DNA and the initial amount of mRNA.
2.4. Measurement of Prostanoids Release from Vascular Segments
The release of prostanoids following Phe stimulation was determined by enzyme immunoassay
(ELISA). Aliquots of Krebs–Henseleit solution were collected after the concentration–response curves
to Phe and kept at room temperature for 30 min for complete hydrolysis of prostacyclin (PGI2) and
thromboxane A2 (TXA2) into their stable metabolites, 6-Keto-PGF1α and TXB2, respectively. Analysis
of specific contributions of COX-1 and COX-2 to prostanoids release was carried out in organ baths
containing vehicle-treated CCA or CCA treated with selective inhibitors of COX-1 or COX-2. Levels
of 6-Keto-PGF1α and TXB2 were assessed in duplicate and calculated according to the ELISA kit
manufacturer (Cayman Chemical, Ann Arbor, MI). The results were expressed as pM for vehicle-treated
CCA and as Log2 of fold change in arteries treated with selective inhibitors of COX-1 (SC396) or
COX-2 (NS398).
2.5. Western Blot Analysis
SDS-PAGE resolved equal amounts of protein from each CCA sample (30 µg) on 4–12% gels and
electroblotted onto nitrocellulose membranes. Membranes were incubated for 1 h (h) with casein-based
blocking buffer, following overnight incubation at 4 ◦C with specific primary antibodies as follows:
polyclonal rabbit anti-ERα36, 1:1000 (Alpha Diagnostic, San Antonio, TX, USA); polyclonal rabbit
anti-ERα66 1:1000 (Santa Cruz Biotechnology, Sta Cruz, CA, USA). After washes, membranes were
incubated with specific horseradish peroxidase-labeled secondary antibodies in phosphate-buffered
saline (PBS) containing 1% casein-based buffer. Following additional washes, the chemiluminescent
signal was visualized by LAS4000 imaging system (GE Healthcare, Chicago, IL, USA). All membranes
were reblotted using a mouse monoclonal antibody anti-α-actin (1:2000; Agilent Dako, Sta Clara, CA,
USA) as the loading control. Densitometric analyses of western blots were performed using ImageJ
software, and data were normalized to corresponding values of αActin densitometry.
2.6. Methylation Status of Gene Encoding ERα and Expression of Splicing Variants
The methylation status of different CpG enriched regions of the gene encoding ERαwas determined
by methylation-sensitive qPCR, as described [16]. Following mock digestion or enzymatic digestion
with HpaII (methylation-sensitive) or MspI (no methylation-sensitive), resulting DNA was amplified
using qPCR with Power SYBR® Green master mix, as described by the manufacturer (Applied
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Biosystems). PCR primers were designed using Methyl Primer Software (Applied Biosystems) to
amplify five distinct CpG enriched regions of ERα gene or to amplify a region that is devoid of any
of the restriction sites of the enzymes used in the design of the experiment, as an internal control
(Table S4, Major Resources Tables). Methylation at CpG sites prevents HpaII, but not MspI, digestion
and allows the amplification of the fragment, resulting in a low cycle threshold (Ct) value. In contrast,
if the CpG island is not methylated, HpaII cleaves DNA and prevents the amplification of the fragment,
resulting in higher Ct values. The percentage (%) of methylation of a given site was determined from
the change in Ct value (∆Ct) of methylated-sensitive and mock digested samples. Taking into account
the fundamental principle that each successive round of PCR amplification results in approximately a
2-fold increase in the amount of product, the % Methylation was calculated as 100 × (2−0.7(∆Ct)). Each
sample was analyzed in duplicate. The expression of wild type ERα and C-terminally truncated ERα
product (CTERP) was determined in mice CCA by SYBR green-based qPCR. For relative quantification,
the amount of CTERP splicing expressed in mice CCA was normalized by the expression of the very
same wild type gene (ERα) and the very same sample, as previously described.
2.7. Data Analysis and Statistics
Data are expressed as mean ± SEM of the number (n) of mice indicated in the figure legends.
The extra sum-of-squares F determined the differences in the fit of concentration–response curves in
all groups. The AUC was calculated for individual contractile or relaxing concentration–response
curves and expressed as arbitrary units. The contribution of different endothelium-derived factors
to Phe-induced contractions was calculated by subtracting the AUC for Phe curves in the presence
of inhibitors from the AUC for control Phe curves (∆Change). Brown–Forsythe testing determined
equality in variances among experimental groups (OVX, E2E, and E2L). One-way ANOVA analyzed
the dependence of data on the onset of estrogen therapy (none, early, or late) in SAMR1 or SAMP8 with
Bonferroni’s post-test. The analysis was carried out using the Prism software (GraphPad Software
V7.0, San Diego, CA, USA), and statistical significance was accepted at p < 0.05.
3. Results
3.1. Basic Parameters for Ovariectomy and Estrogen Treatment Efficacy
Ovariectomy resulted in reduced uterine weight and plasma 17β-estradiol concentrations in
SAMR1 and SAMP8 female mice (data not shown). Those parameters were restored by both early
(E2E) and late (E2L) onset of 17β-estradiol treatment (Table 1).
Table 1. Basic parameters (uterus weight and estrogen plasma concentration).
SAMR1 SAMP8
OVX E2E E2L OVX E2E E2L
Uterus wet weight
(mg/cm) 30.1 ± 4.5 49.5 ± 5.4 * 56.1 ± 7.1 * 14.0 ± 1.7 42.4 ± 5.7 * 40.3 ± 5.5 *
Uterus dry weight
(mg/cm) 7.9 ± 1.1 12.3 ± 1.0 * 13.9 ± 1.6 * 4.3 ± 0.8 12.1 ± 1.8 * 11.0 ± 1.2 *
17β-estradiol
(pg/mL) 2.1 ± 0.5 4.2 ± 0.9 * 7.0 ± 1.2 * 1.2 ± 0.3 9.8 ± 1.4 * 7.4 ± 0.9 *
Values are means ± SEM of samples from 10 animals per group. The uterus weight was normalized by tibia length
(mg tissue/cm tibia). The analysis was obtained in untreated ovariectomized mice (OVX), and ovariectomized mice
under early-onset (E2E) or late-onset of 17β-estradiol treatment (E2L). * p < 0.05 vs. OVX.
Cells 2019, 8, 1217 6 of 17
3.2. Early- and Late-Onset Estrogen Treatments Promote Different Vasoconstrictor Effects in Response to
Adrenergic Stimulus in SAMR1 and SAMP8 Ovariectomized Female Mice
To determine how the onset of estrogen therapy affects the vascular function of senescent and
non-senescent females, we tested the responses of CCA to different vasoactive agents. All agonists
studied induced concentration-dependent responses in CCA rings in either group. In SAMR1,
treatments with either E2E or E2L reduced the contractile response to Phe, compared to untreated
OVX (Figure 1A), as demonstrated by the smaller area under the curves (Figure 1C). In SAMP8,
responses to Phe after E2E treatment were similar to those observed in the OVX group. However, E2L
treatment increased Phe vasoconstriction when compared to the OVX group (Figure 1B,C). On the
other hand, there were no differences in the vasoconstrictor responses to the thromboxane A2 analog
U46619 (Figure S1). Neither did we observe significant differences in vasodilatation responses to both
endothelium-dependent (ACh) and endothelium-independent (SNP) agents (Figure S2).
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Figure 1. Phenylephrine-induced contractions. Concentration–effect curves to Phenylephrine (Phe)
determined in endothelium-intact common carotids arteries from SAMR1 (A) and SAMP8 (B) female
mice. Curves were obtained in vessels from untreated ovariectomized mice (OVX), and ovariectomized
mice receiving early-onset (E2E) or late-onset (E2L) of 17β-estradiol treatment. Differences in vascular
responses are xpressed as the ar a under th curve (AUC) (C). Each point of the curve and bar
graphs r pres nts the mean ± SEM from 10–18 independent experiments. Th extra sum-of-squares F.
One-way ANOVA determined differences in the fit of concentration–response cu ves analyzed the
dependence of data on the onset of estrogen therapy (none, early, or late) in SAMR1 or SAMP8 with
Bonferroni’s post-test. p-values and comparisons are expressed next to the curves and on top of bar
graphs. Significance is considered when p < 0.05.
3.3. Estrogen Differently Regulates the Contribution of NO/Superoxide Anion (O2−) Pathways to Phe
Contraction in Non-Senescent (SAMR1) and Senescent (SAMP8) Carotids
Inhibition of NO production by L-NAME increased the vasoconstrictor responses to Phe in
all groups of SAMR1 (Figure 2A) and SAMP8 (Figure 2B) female mice. The ∆Change in the AUC
(Figure 2C) shows that there is a more significant contribution of NO to attenuate contractile responses
in arteries of non-senescent females (SAMR1) treated with both E2E and E2L than in untreated
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OVX-SAMR1. In SAMP8, the ∆Change in the AUC of E2E was similar to untreated mice. In opposition,
E2L displayed a lower ∆Change in the AUC compared to untreated OVX-SAMP8, suggesting a smaller
contribution of NO to Phe contraction in this group (Figure 2C). Variations in the contribution of NO to
vascular reactivity could be related to changes in both NO production, either via eNOS upregulation
or downregulation, and modulation of NO scavenging by O2−. Analysis of mRNA expression showed
an increase in eNOS expression in estrogen-treated groups in SAMR1, but not in SAMP8 (Figure 2D).
The influence of O2− on Phe-induced contractions was assessed by performing contractile curves in
the presence of O2− scavenger, tempol. Incubation with tempol decreased Phe contractions in CCA of
non-senescent untreated OVX, without affecting vasoconstrictor responses in estrogen-treated SAMR1
(Figure S3). In senescent females, scavenging of O2− by tempol decreased contractions to Phe in all
SAMP8 groups (Figure S3).
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Figure 2. Role of NO in phenylephrine-induced contractions. Concentration–response curves to
phenylephrine (Phe) in endothelium-intact common carotid artery from SAMR1 (A) and SAMP8 (B).
Arteries were isolated from untreated ovariectomized mice (OVX), or OVX treated with early-onset
of 17β-estradiol treatment (E2E) or late-onset 17β-estradiol treatment (E2L). Curves were obtained
in the absence or the presence of L-NAME (10−4 M). The contribution of NO to Phe contraction is
expressed as the change (∆ Change) in the area under the curve in L-NAME treated arteries relative to
untreated arteries (C). mRNA levels of eNOS (D) normalized by β-actin mRNA and relative to the
expression of untreated OVX mice. Each point represents the mean ± SEM from 8–17 independent
experiments. The extra sum-of-squares F determined differences in the fit of concentration–response
curves. One-way ANOVA analyzed the dependence of data on the onset of estrogen therapy (none,
early or late) in SAMR1 or SAMP8 with Bonferroni’s post-test. p-values and comparisons are expressed
next to the curves and on top of bar graphs. Significance is considered when p < 0.05.
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3.4. Senescence and Onset of Estrogen Therapy Play an Important Role in Regulating the Contribution of
Vasodilator and Vasoconstrictor Prostanoids to Phe Contraction
We next sought to determine the contribution of prostanoids metabolites to the regulation of
Phe contraction by estrogen, and how their contributions are affected by vascular senescence and
therapy onset. Accordingly, CCAs were treated with the unspecific inhibitor of cyclooxygenases (COX)
indomethacin. Pre-incubation with indomethacin decreased Phe contraction in estrogen-untreated
OVX-SAMR1 and all three groups of SAMP8 (Figure S4), suggesting a predominance of COX-derived
vasoconstrictor metabolites. The specific role of COX isoenzymes to Phe contractions was then
determined by treating CCA with the selective inhibitors of COX-1 (SC560) or COX-2 (NS398).
In SAMR1, COX-1, but not COX-2, inhibition reduced vasoconstrictor responses in untreated OVX,
indicating a contribution of COX-1-derived vasoconstrictor prostanoids to Phe-induced contractions
(Figure 3A,D). On the contrary, Phe contraction in E2E was modulated by a COX-2-derived vasodilator
(Figure 3B,E). Late-onset of estrogen treatment (E2L) modified prostanoids’ contribution to Phe
vasoconstriction by increasing both COX-1- and COX-2-derived vasodilators (Figure 3C,F). In the
senescent CCA from SAMP8, both COX inhibitors reduced vasoconstriction to Phe only in the E2L group
(Figure 3I,L). Inhibition of either COX-1 or COX-2 did not affect contractions in arteries form untreated
OVX-SAMP8 (Figure 3G,J) or SAMP8 E2E (Figure 3H,K). mRNA expression analysis of the major
enzymes involved in the prostanoids’ biosynthesis cascade revealed differential regulation by estrogen
in non-senescent and senescent CCA (Figure 4). Estrogen therapy increased the expression of COX-2 in
SAMR1 (Figure 4B) and augmented the expression of TXA2 synthase in SAMP8 (Figure 4D). In contrast,
no changes in the expression of COX-1 (Figure 4A) or PGI2 synthase (Figure 4C) were observed.
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Figure 3. Role of COX-derived pros landins in phenylephrine-induced contractions.
Concentration–response curves to phenylephrine (Phe) in the endotheliu -intact common carotid artery
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from SAMR1 (A–F) and SAMP8 (G–L). Arteries were isolated from untreated ovariectomized mice
(OVX) or treated with early-onset of 17β-estradiol treatment (E2E) or late-onset 17β-estradiol treatment
(E2L), as indicated. Curves were obtained in the absence or the presence of COX-1 (SC560, 10−6 M) or
COX-2 (NS 398, 10−6 M) inhibitor. Inset graphs represent the areas under the curve (AUC) obtained
from the curves of untreated carotids (NT) or those receiving selective COX inhibition. Each point
represents the mean± SEM from 5–10 independent experiments. The extra sum-of-squares F determined
differences in the fit of concentration–response curves. One-way ANOVA analyzed the dependence
of data on the onset of estrogen therapy (none, early, or late) in SAMR1 or SAMP8 with Bonferroni’s
post-test. p-values and comparisons are expressed next to the curves and on top of bar graphs.
Significance is considered when p < 0.05.Cells 2019, 8, 1217 10 of 18 
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Figure 4. mRNA expression in cyclooxygenase cascade. COX-1 (A), COX-2 (B), PGI2S (C), and TXA2S
(D) expression in common carotid artery of SAMR1 and SAMP8 normalized by β-actin mRNA and
relative to the expression of untreated OVX mice. Total RNA as obtained in vessels from untreated
ovariectomized femal mice (OVX), OVX mice rec iving early- β-estradiol treatment (E2E),
and OVX mice receiving late-ons t 17β-estradiol treatment (E2L). Each point represents he mean± SEM
from 5–10 independe t experiments. One-way ANOV analyzed the ependence of data on the onset
of estrogen therapy (none, early, or late) in SAMR1 or SAMP8 with Bonferroni’s post-test. p-values and
comparisons are expressed on top of bar graphs. Significance is considered when p < 0.05.
3.5. Dual Effect of COX-1 and COX-2 in Prostanoids Production
Prostanoids release from CCA was determined in the Krebs–Henseleit solution collected after
concentration–response curves to Phe. In SAMR1, E2E increased the release of PGI2 by ~2-fold, while
it decreased the TXA2 released by Phe by ~3-fold in comparison to untreated OVX. Late-onset estrogen
therapy did not produce the inhibitory effects of estrogen on TXA2 release in untreated OVX-SAMR1,
even though it increased PGI2 concentration. In senescent CCA, neither early nor late-onset estrogen
treatments modified PGI2 release (Supplementary Figure S5), whil E2L increased TXA2 c ncentration
induced by Phe stim lation (Supplem ntary Figure S6). Selective inh bition of COX-1 and COX-2
produced a differential regulation of prostanoids biosynthesis depe ding on the onset of estrogen
therapy in non-senescent and senescent arteries. In SAMR1, increased release of PGI2 by E2E and E2L
was mainly dependent on COX-2, since the degree of change in PGI2 production (Log Fold Change)
upon estrogen treatment was only observed when the CCAs were inhibited with NS398. In SAMP8,
both COX-1 and COX-2 inhibitors similarly decreased PGI2 production in all groups (Figure S5). As for
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TXA2, COX-1 is the primary regulator of its production in CCA of OVX-SAMR1 (Figure S6). On the
other hand, the increase in TXA2 observed upon E2L treatment in SAMP8 was regulated by COX-2
(Figure S6).
3.6. Late-Onset Estrogen Treatment Increases Alternative Splicing of Estrogen Receptor Alpha (ERα36) in Aging
Most of the vascular protective effects of estrogens are mediated through interaction with ERα.
We next evaluated how senescence and therapy onset modify ERα expression. Analysis of methylation
sites in the gene encoding ERα by methylation-sensitive quantitative PCR showed a marked increase
of methylation in the region corresponding to Exon 8 in senescent arteries (Figure 5A). The early onset
of estrogen treatment further increased the degree of methylation in the CAA of OVX-SAMP8. In order
to determine whether changes in the degree of methylation of the ERα gene can affect the pattern of
receptor expression, we analyzed mRNA and protein expression of wild-type ERα and its alternative
splicing. The onset of estrogen therapy did not change gene (Supplementary Figure S7) or protein
(Figure 5C) expression of the wild-type ERα (ERα-66kDa) in CCA. Gene expression of the variant
splicing ERα-36kDa was marked lower relatively to the wild-type receptor in most groups, except
SAMP8 E2L, which exhibited a 6-fold increase over the expression of the wild type ERα (Figure 5B).
Changes in mRNA expression of ERα-36kDa corresponded to the pattern of protein expression
(Figure 5D). No changes in the expression of the variant ERα-46kDa were found (Figure 5C).
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Figure 5. Transcriptional and post-transcriptional regulation of ERα. Percentage of specific DNA
methylation in the gen encodi g ERα in common carotid artery of SAMR1 and SAMP8 (A). Bar graphs
show the percentag (%) of methylation in the region comprised b tw en xon 7 and exon 8 and
transl ted to the C-terminus. mRNA expression of C-terminall tr cated ERα product (CTERP)
relative to the expression of wild-type (ERα66) in mice carotid (B). Protein expression of the classical
ERα66 and the alternative splicing variants ERα46 (C) and ERα36 (D) in common carotid normalized by
the expression of α-actin. Samples of genomic DNA, total RNA or protein were obtained in vessels from
untreated ovariectomized mice (OVX), ovariectomized mice under early-onset (E2E) or late-onset (E2L)
of 17β-estradiol treatment. Each point represents the mean ± SEM from 5–7 independent experiments.
One-way ANOVA analyzed the dependence of data on the onset of estrogen therapy (none, early,
or late) in SAMR1 or SAMP8 with Bonferroni’s post-test. p-values and comparisons are expressed on
top of bar graphs. Significance is considered when p < 0.05.
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4. Discussion
In this study, we describe that the onset of estrogen therapy modifies the vascular function of
ovariectomized senescent female mice (SAMP8). Our findings are consistent with new clinical studies
suggesting that the beneficial effects of estrogen therapy in the cardiovascular system depend on the
time when therapy is initiated [14]. Our data show that estrogen reduces constriction to the adrenergic
stimulus by Phe in the CCA of non-senescent OVX mice, regardless of treatment onset, by favoring
the release of endothelium-derived relaxing factors, such as NO and PGI2. Nonetheless, onset timing
plays a critical role when arteries are senescent, a more representative model of arteries in menopausal
women. In CCA of senescent female mice (SAMP8), late-onset of estrogen treatment increases
adrenergic vasoconstriction in association with augmented TXA2 production and upregulation of
ERα36 expression, alternative splicing of the classical ERα.
Estradiol, also known as E2 or 17β-estradiol, has been widely used as a therapeutic choice for
postmenopausal women seeking amelioration of many different menopause-associated symptoms,
including vasomotor symptoms, vaginal atrophy, and prevention of osteoporosis [23]. Because
premenopausal women are less likely to progress to cardiovascular disease, a protective cardiovascular
effect by estrogen was proposed in the past involving a myriad of different mechanisms [24].
Nevertheless, important randomized and placebo-controlled trials—including the WHI and
HERS—raised doubts and concerns about the use of estrogen in the primary and secondary prevention
of cardiovascular disease [10,11]. More importantly, the WHI study alerted about the increased risk of
stroke not offset by the lower risk of coronary heart disease. The surprising controversies on the risks
and benefits of estrogen therapy are, in part, associated with the time of its initiation. Detailed analysis
of the WHI showed a significantly lower risk of coronary heart disease by estrogen therapy among
women who were less than 10 years past the onset of menopause, and therefore, less time devoid of
estrogen actions [12]. Reinforcing this analysis are the results of the ELITE trial specifically designed to
test the hormone-timing hypothesis concerning cardiovascular risk in postmenopausal women [14].
Despite growing evidence validating the existence of a window of therapeutic opportunity for the
cardiovascular benefits by estrogen, we still need to understand the mechanisms behind it.
Vascular aging has been associated with a series of progressive functional alterations that can
modify estrogen signaling in the arterial wall [25]. Considering that women enrolled in the clinical
trials on hormone therapy and cardiovascular protections were middle-aged and had long been in
menopause, it becomes difficult to separate the contribution of senescence from the long-term estrogen
withdrawal to the adverse cardiovascular outcomes observed. In previous studies, we described that
senescence dampens the beneficial effects of estrogen in aortas of OVX female mice [16]. However, we
still do not know how senescence could modulate the risk-benefit ratio of estrogen use in arteries that
are important for cerebral perfusion. Arteries of the distinct sizes and in distinct beds are regulated
differently by intrinsic stimuli (including adrenergic stimulation) [26] and by the aging process [27];
therefore, it is of the utmost importance to understand the mechanisms of estrogens in the different
senescent vascular beds, and more specifically in the cerebrovasculature. In this regard, we aimed to
determine how the time to initiate estrogen treatment shapes estrogen-mediated effects in CCA of both
non-senescent and senescent females. We used the OVX-SAMP8 as a model of menopause, based on
our previous studies establishing OVX-SAMP8 as a suitable model to concomitantly study the effects
of senescence and estrogen deficiency in middle-aged females [21].
In our preliminary studies in the carotid reactivity, we observed that basal response to estrogen
might vary depending on mice strain (SAMR1 or SAMP8). When we compared the maximal contraction
to Phe in carotid rings from intact (non-ovariectomized) SAMR1 and SAMP8 we observed that the
maximal contractile response to Phe was markedly higher in intact SAMP8 (106 ± 5.2%) in comparison
to intact SAMR1 (81 ± 1.8%, p < 0.0001), suggesting a detrimental effect of senescence in this vascular
bed. Curiously, OVX did not modify the contractile response in SAMR1 (82.2 ± 2.3%, p = 0.812), while
it deceased Phe contraction in SAMP8 (78.8 ± 1.8%, p < 0.001). Together, these results propose that
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estrogen plays a differential role in the control of vascular reactivity in young and senescent carotid
arteries, even when at physiological levels.
A correlation between senescence and vascular dysfunction has been extensively described in
men and women and much associated with decreased NO-mediated vasodilation [15,28]. Intact
(non-ovariectomized) SAMP8 female mice presented a faster and time-dependent decrease in NO
and increased oxidative stress compared to SAMR1 [29]. Estrogen withdrawal suppresses the
involvement of NO in both groups [30], suggesting an overlap between aging and hormonal levels to
control NO-mediated vascular function, similar to what is observed in postmenopausal women [31].
When females are non-senescent (SAMR1), estrogen therapy improves the vascular function of CCA
(decreased Phe vasoconstriction) and augment NO bioavailability, via both upregulation of eNOS and
decreased oxidative stress. Corroborating our data in SAMR1, several experimental studies in different
vascular systems of young ovariectomized animal models show protective effects by estrogens in the
aorta [5,32–34], mesenteric microvessels [8] and veins [9].
On the other hand, when females are senescent, estrogen treatment does not fully restore NO
bioavailability in CCA. The reasons for this effect are unclear but may be related to the age-associated
phenotypic changes in the vascular wall that diminish responsiveness [6,35] or modify signaling
for estrogens [16]. In previous studies, we found that estrogens lose its ability to modulate eNOS
expression, while significantly increases NADPH oxidase 1 (NOX1) expression and, consequently,
the production of O2− in aortas of OVX-SAMP8 mice [16].
In addition to NO, the cyclooxygenase (COX)-prostanoid cascade has also been implicated
in the pathophysiology of vascular dysfunction during aging [36,37] and following estrogen
withdrawal [7]. As revised by Hermenegildo and colleagues [38], estrogen increases the production of
the COX-derived vasodilators PGI2 in different vascular beds—such as uterine, mesenteric, cerebral,
and aortic—supporting additional benefit by this hormone in the female vasculature, whereas PGI2
metabolite levels decrease in postmenopausal women [39]. Moreover, PGI2 has been associated with the
atheroprotective effect of estrogen [40]. In CCA of non-senescent SAMR1, COX-1 inhibition decreases
Phe contraction, revealing an imbalance towards COX-1-derived vasoconstrictor prostanoids generation
when estrogen is withdrawn by OVX. In contrast, COX-2 inhibition increases vasoconstriction in
estrogen-treated SAMR1, suggesting an increased COX-2-derived vasodilator production by estrogen.
Estrogen increased COX-2 mRNA expression in CCA of SAMR1 female, regardless of the timing for
therapy initiation, which is associated with a marked increase of PGI2 concentration in the organ bath
after Phe stimulation. Estrogen increases COX-2–mediated PGI2 production in both human endothelial
cells [41] and mice artery [40].
On the other hand, the senescent carotids of SAMP8 show a different relationship between estrogens
and prostanoids production. Our preliminary data using nonspecific COX inhibitor (indomethacin)
agree with other studies describing an increase of COX-derived vasoconstrictor products by aging and
estrogen withdrawal, as indomethacin decreases Phe-induced vasoconstriction in all SAMP8 groups.
However, when we used selective COX-1 or COX-2 inhibitors, we did not see any change in Phe
responses in CCA of OVX and E2E-treated SAMP8. Only in arteries of E2L females, both inhibitors
decrease vasoconstrictor responses. These results suggest crosstalk between COX-1 and COX-2 in
senescent arteries that maintain vasoconstriction when one or another is inhibited. Nevertheless,
this compensation is missing in senescent females when they receive a late onset of estrogen therapy.
The responses in E2L were associated with an increase of TXA2 synthase expression and TXA2
production after challenge with Phe. Augmented TXA2 production was previously reported in intact
six months old SAMP8 female mice, and nonspecific COX inhibition corrected this parameter [29].
In postmenopausal women, estrogen increases platelet activation via TXA2 production [42]. In contrast,
another study demonstrated that estrogen does not change TXA2 production in cultured human
endothelial cells [43]. Together, these results suggest that the effects of estrogen on TXA2 production
may depend on cell/tissue type and pathophysiological condition.
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The primary receptor responsible for the vascular actions of estrogens is the ERα, despite many
studies describing vascular actions of ERβ and GPER [17]. Studies with ERα knockout [44] and Cre-lox
recombinant endothelium-specific ERα knockout flox/flox (CreLoxP) mice [45] have demonstrated that
ERα is necessary for estrogen-induced reendothelialization and vascular protection. Moreover, ERα
activation has been associated with increased eNOS transcription and NO production [46], antioxidant
effects [47], and regulation of prostanoids production [48], reinforcing that ERα activation is essential
for most of the beneficial actions of estrogens in the vasculature. Expression of ERα is subject to
complex regulation since the gene encoding this receptor subtype has a multiple promoter system,
which produces distinct splicing variants during transcription. The two most-studied ERα isoforms
are the 46Kd (ERα46) and the 36Kd (ERα36) receptors. ERα46 lacks the transcriptional activation
function-1 (AF-1) in the N-terminus, while ERα36 misses both AF-1 and part of AF-2 in the C-terminal
portion of the receptor. Thus, these variants may have limited transcriptional activity and can oppose
genomic actions of the full-length 66Kd (ERα66) [17]. Disruption in estrogen signaling by upregulation
of these splicing has been associated with cancer [20]. The pattern of ERα66 expression and its splicing
might also be a determining factor in the aging process. It is known that alternative splicing is a typical
post-transcriptional process in eukaryotes that can be associated with premature aging and associated
diseases [49]. However, the contribution of alternative variants of ERα to women’s vascular health and
disease remains an open question.
In the present study, we described for the first time that the CCA of female mice expresses
both ERα46 and ERα36 variants. The expression of ERα36 mRNA was markedly lower relative to
wild-type ERα66 in all experimental groups of SAMR1 mice. However, in senescent CCA late onset of
estrogen treatment increased ERα36 expression to levels that were higher than the wild type receptors.
The upregulation of ERα36 in E2L-SAMP8 was parallel by both increased TXA2 production and
Phe vasoconstriction. Although we cannot provide direct evidence on the role of ERα36 on TXA2
production, due to the lack of specific agonist/antagonist for ER36, the fact that the expression of
this variant is increased only in the group where we observed increased TXA2 release, points to a
plausible relationship between these two pathways. Anti-ERα36 antibody treatment was shown to
reduce estrogen-induced vasodilation in middle cerebral arteries from male rats [50]. Even though this
study supports the vascular role of ERα36, the molecular mechanisms regulated by this specific ERα
variant in the vascular wall warrant further examination.
In summary, this study demonstrates that timing to initiate the treatment is a determining factor
for the detrimental or beneficial effects of estrogens. More specifically, when arteries are senescent,
late-onset estrogen therapy may represent a risk to the vasculature for increasing the production of
contractile factors and vasoconstriction. Although we do not have direct evidence, the detrimental
effects of estrogen are in parallel with an increase in expression of ERα36, which could plausibly
modify estrogen signaling pathways towards vascular impairment. On average, women are living
20 years in menopause, and the use of estrogen in this population has been widely used to lessen
problems associated with this natural process. This study draws our attention to the need for increasing
our understanding of the mechanisms of action of estrogen receptors and their variants during
cardiovascular aging in women. Because of the great controversy and the gap in the knowledge of
the risks/benefits of estrogen use in the cardiovascular system, our results are of significant scientific
impact. Besides, our results provide new insights into the regulation of estrogen receptors in aging
and disease, which may eventually lead to the development of new regulatory molecules acting on
estrogen receptors to improve vascular health in women and men.
5. Translational Perspective
The risk or benefit for estrogen use in menopausal women remain controversial, and the modulation
of estrogen signaling in healthy, aged, and diseased vasculature is still unknown. In precision medicine
times, we still do not know which population of women would benefit from the use of estrogen and
in which one hormone therapy would pose a cardiovascular risk. This study shows that timing to
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initiate estrogen treatment is a determining factor for the detrimental or beneficial effects of estrogens
and provide new insights into the regulation of estrogen receptors in aging and disease, which may
eventually lead to the development of new regulatory molecules acting on estrogen receptors to
improve vascular health in postmenopausal women.
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